|

NP-G2-044 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Prilukae

Pipeline

Phase 2/3: 1

Top Sponsors

  • Novita Pharmaceuticals, Inc.1

Indications

  • Platinum-resistant Ovarian Cancer1
  • Cancer1

Phoenix, Arizona1 trial

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

HonorHealth Cancer Care

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.